MLN 133
Alternative Names: MLN-133Latest Information Update: 31 Mar 2022
Price :
$50 *
At a glance
- Originator Cannabics Pharmaceuticals
- Developer CNBX Pharmaceuticals
- Class Antineoplastics; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 28 Mar 2022 Cannabics Pharmaceuticals is now called CNBX Pharmaceuticals
- 07 Oct 2021 Cannabics Pharmaceuticals plans for submission of pre-IND meeting request with US FDA (Cannabics Pharmaceuticals pipeline)
- 07 Oct 2021 Cannabics Pharmaceuticals plans a Proof of Concept (POC) study using in vivo animal models in Melanoma(Cannabics Pharmaceuticals pipeline)